On October 30, 2025 Synthekine Inc., an engineered cytokine therapeutics company, reported that data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, will be presented in a late-breaking oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2025 taking place in National Harbor, MD., from November 7-9, 2025. In this study, STK-012 is being evaluated in combination with standard-of-care pembrolizumab + chemotherapy in first-line, PD-L1 negative nonsquamous non-small cell lung cancer (NSCLC) patients. The company will also present new preclinical data on combinations of STK-012 and T cell engagers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present our first clinical data in first-line, PD-L1 negative nonsquamous NSCLC patients from the ongoing trial of STK-012, our lead program and a novel approach to biasing IL-2," said Debanjan Ray, chief executive officer of Synthekine. "PD-L1 negative patients comprise approximately one-third of the nonsquamous NSCLC population, and these patients receive significantly reduced benefit from standard-of-care chemoimmunotherapy versus PD-L1 positive patients. We look forward to sharing these results with the scientific community, and the further development of STK-012 in this setting in our SYNERGY-101 study, a global, randomized Phase 2 trial which is currently ongoing."

Details are as follows and available on the SITC (Free SITC Whitepaper) online itinerary:
(Please note that the late-breaking clinical data will be shared both as an oral presentation and a poster.)

Title: Initial Phase 1a/1b Results of STK-012, an α/β IL-2 Receptor Biased Partial Agonist, with Pembrolizumab, Pemetrexed, and Carboplatin in 1L PD-L1 Negative Non-Squamous NSCLC
Session Title: Clinical Oral Abstract Session 2
Session Date & Time: Saturday, November 8, 2025, 2:00 PM ET
Location: Gaylord National Resort and Convention Center, Potomac Ballroom
Abstract Number: 1345

Title: Initial Phase 1a/1b Results of STK-012, an α/β IL-2 Receptor Biased Partial Agonist, with Pembrolizumab, Pemetrexed, and Carboplatin in 1L PD-L1 Negative Non-Squamous NSCLC
Session Title: Exhibits and Poster Reception
Session Date & Time: Friday, November 7, 2025, 5:35 PM – 7:00 PM ET
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
Poster Board Number: 1345
Abstract Number: 1345

Title: STK-012, a First-in-Class α/β IL-2 Receptor Biased Partial Agonist Enhances the Anti-Tumor Efficacy of Bispecific Antibodies
Session Title: Exhibits and Poster Reception
Session Date & Time: Saturday, November 8, 2025, 5:10 PM – 6:35 PM ET
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
Poster Board Number: 682
Abstract Number: 682

Copies of the presentation and posters will be available on Synthekine’s website following presentation at the meeting.

(Press release, Synthekine, OCT 30, 2025, View Source [SID1234657187])